You are here

Article Text

Article menu
Download PDFPDF
Prevention
Cohort study
Combined HPV and cytology better than cytology for protection against cervical cancer
  1. Mack Ruffin
  1. Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to: Dr Mack Ruffin, Department of Family Medicine, University of Michigan, 1018 Fuller Street, Ann Arbor, MI 48104-1213, USA; mruffin{at}umich.edu

https://doi.org/10.1136/eb-2014-101792

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.OpenUrlCrossRefPubMedWeb of Science

    Context

    Over the past 20 years, cervical cancer screening guidelines have evolved from advising performance of cervical cytology on every sexually active woman every year, to advising no screening on women under the age of 21 years and use of cervical cytology every 3 years only in women aged 30–65 years with an intact cervix.1 Many clinicians use human papillomavirus (HPV) testing with cervical cytology to triage abnormal cytology. Others have begun to use HPV alongside normal cytology. The data to support this strategy was based solely on protection from cervical …

    View Full Text

    Footnotes

    • Competing interests None.